Search | Clinical Trials Finder

Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Interventions: Eplontersen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 1,438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 51
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 39 more

Conditions: Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies
Interventions: Acoramidis, Placebo oral tablet; Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 40
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 31 more

Conditions: Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related, Familial Transthyretin Cardiac Amyloidosis
Interventions: Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 41
States / cities: Bakersfield, California • Beverly Hills, California • La Mesa, California + 30 more

Conditions: Polyneuropathies, Wild Type ATTR Amyloidosis, Wild-Type Transthyretin-Related (ATTR)Amyloidosis, Wild-Type Transthyretin Cardiac Amyloidosis, Transthyretin Amyloidosis
Interventions: patisiran; Drug
Lead sponsor: Austin Neuromuscular Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hereditary Transthyretin-mediated (ATTRv) Amyloidosis, Polyneuropathy
Interventions: Patisiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 27
States / cities: Los Angeles, California • San Diego, California • Aurora, Colorado + 22 more

Conditions: Familial Amyloidotic Cardiomyopathy (FAC)
Interventions: Not listed
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 43
States / cities: Little Rock, Arkansas • Bakersfield, California • La Mesa, California + 32 more

Conditions: ATTR-PN
Interventions: Tafamidis; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions: Placebo, Patisiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 19
States / cities: Los Angeles, California • Chicago, Illinois • Skokie, Illinois + 14 more

Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Interventions: Cardiac MRI; Diagnostic Test
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • Portland, Oregon

Conditions: Transthyretin-mediated Amyloidosis With Cardiomyopathy, ATTR Amyloidosis With Cardiomyopathy
Interventions: Patisiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 17 more

Conditions: Amyloidosis, Transthyretin Amyloidosis
Interventions: 124I-Evuzamitide; Diagnostic Test
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 40 Years to 90 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Interventions: ALXN2220; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 1,180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 35
States / cities: Irvine, California • La Jolla, California • Palo Alto, California + 29 more

Conditions: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Interventions: Tafamidis; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Transthyretin Amyloid Cardiomyopathy
Interventions: Empagliflozin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Interventions: NNC6019-0001; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • Stanford, California + 5 more

Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Interventions: NNC6019-0001, Placebo (NNC6019-0001); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 9
States / cities: Phoenix, Arizona • Beverly Hills, California • Stanford, California + 5 more

Conditions: Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases
Interventions: acoramidis, Placebo Oral Tablet; Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 632 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 40
States / cities: Los Angeles, California • Santa Monica, California • Aurora, Colorado + 32 more

Conditions: TTR Cardiac Amyloidosis
Interventions: Biotronik Biomonitor 3 implant of device, Biotronik Biomonitor 3 explant of device; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Familial ATTR-CM (ATTRm-CM, or FAC), Wild-type ATTR-CM (ATTRwt-CM)
Interventions: AG10, Placebo Oral Tablet; Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 13
States / cities: Beverly Hills, California • Palo Alto, California • San Francisco, California + 9 more

Conditions: Transthyretin Amyloid Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
Interventions: Scintigraphy; Diagnostic Test
Lead sponsor: Pfizer; Industry
Eligibility: 60 Years and older
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 22
States / cities: Fairhope, Alabama • Huntsville, Alabama • Miami, Florida + 11 more

Conditions: ATTR, ATTR Gene Mutation, Cardiomyopathy, Transthyretin Mediated Amyloidosis (ATTR)
Interventions: Iodine-124 Evuzamitide (I-124E); Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 30 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed, hATTR
Interventions: Treatment of transthyretin (ATTR) amyloidosis in observational study setting; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 33
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 24 more

Conditions: HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy, Cardiac Amyloidosis
Interventions: Not listed
Lead sponsor: eMyosound SAS; Industry
Eligibility: 60 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis
Interventions: Not listed
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2033
U.S. locations: 13
States / cities: La Jolla, California • Los Angeles, California • Jacksonville, Florida + 10 more

Search by objective public record fields.

CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy

A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation

DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis

APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy

Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

Long-term Monitoring of Patients With Cardiac Amyloidosis With Implantable Event Monitors

Study of AG10 in Amyloid Cardiomyopathy

Global Prevalence of ATTR-CM in Participants With HFpEF

PET/CT Imaging in Carriers of TTR Mutations

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

US Benchmarking Clinical Study

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)